Disrupting the CD47-SIRPα axis enables macrophage phagocytosis, induces phenotype switch from M2 to M1 TAMs [77,83,145], reduces CAR cell therapy resistance, and improves NK cell anti-tumor activity [78] (Table 1). Here, SIRPA is linked to neoplasm.